

Laura Orsolini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5689522/publications.pdf>

Version: 2024-02-01

132
papers

4,055
citations

159585

30
h-index

149698

56
g-index

140
all docs

140
docs citations

140
times ranked

4828
citing authors

#	ARTICLE	IF	CITATIONS
1	Scaling Up Global Mental Health Services During the COVID-19 Pandemic and Beyond. <i>Psychiatric Services</i> , 2022, 73, 231-234.	2.0	24
2	Fear During COVID-19 pandemic: Fear of COVID-19 Scale Measurement Properties. <i>International Journal of Mental Health and Addiction</i> , 2022, 20, 2493-2502.	7.4	4
3	How is the COVID-19 pandemic affecting women's menstrual cycles and quality of life? A view from South Asia. <i>BJ Psych Advances</i> , 2022, 28, 274-277.	0.7	6
4	C-Reactive Protein as a Biomarker for Major Depressive Disorder?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1616.	4.1	39
5	COVID-19-Related Social Isolation Predispose to Problematic Internet and Online Video Gaming Use in Italy. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1539.	2.6	31
6	A Preliminary Italian Cross-Sectional Study on the Level of Digital Psychiatry Training, Knowledge, Beliefs and Experiences among Medical Students, Psychiatry Trainees and Professionals. <i>Healthcare (Switzerland)</i> , 2022, 10, 390.	2.0	5
7	Depressive and Anxious Temperaments as Predictors of Late Onset Bipolar Disorder? Preliminary Results of a "Real World" Exploratory Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 836187.	2.6	1
8	Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 241-244.	2.3	7
9	A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy. <i>Asian Journal of Psychiatry</i> , 2022, 72, 103121.	2.0	7
10	Associations of lockdown stringency and duration with Google searches for mental health terms during the COVID-19 pandemic: A nine-country study. <i>Journal of Psychiatric Research</i> , 2022, 150, 237-245.	3.1	18
11	Public health approaches and policy changes after the inclusion of gaming disorder in ICD-11: global needs. <i>BJPsych International</i> , 2022, 19, 63-66.	1.4	10
12	Towards an International Consensus on the Prevention, Treatment, and Management of High-Risk Substance Use and Overdose among Youth. <i>Medicina (Lithuania)</i> , 2022, 58, 539.	2.0	5
13	Craving and addictive potential of esketamine as side effects?. <i>Expert Opinion on Drug Safety</i> , 2022, 21, 803-812.	2.4	3
14	COVID-19 and Youth Psychopathological Distress in Umbria, Central Italy: A 2-Year Observational Study in a Real-World Setting. <i>Frontiers in Psychiatry</i> , 2022, 13, .	2.6	0
15	Recognizing, Managing and Treating Acute Agitation in Youths. <i>Current Pharmaceutical Design</i> , 2022, 28, .	1.9	0
16	Hikikomori and modern-type depression in Italy: A new phenotypical trans-cultural characterization?. <i>International Journal of Social Psychiatry</i> , 2022, 68, 1010-1017.	3.1	17
17	The grief experience during the COVID-19 pandemic across different cultures. <i>Annals of General Psychiatry</i> , 2022, 21, .	2.7	17
18	COVID-19 related mental health issues: a narrative review of psychometric properties of scales and methodological concerns in scale development. <i>Australasian Psychiatry</i> , 2021, 29, 326-332.	0.7	7

#	ARTICLE	IF	CITATIONS
19	Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 174-178.	2.0	28
20	Alcohol and Tobacco Use During the COVID-19 Pandemic. A Call for Local Actions for Global Impact. <i>Frontiers in Psychiatry</i> , 2021, 12, 634254.	2.6	24
21	Psychological distress experienced by self-quarantined undergraduate university students in Lebanon during the COVID-19 outbreak. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 172-179.	2.4	13
22	Internet and Pornography Use During the COVID-19 Pandemic: Presumed Impact and What Can Be Done. <i>Frontiers in Psychiatry</i> , 2021, 12, 623508.	2.6	37
23	COVID-19 and Cognitive, Emotional Aspects of Post-Intensive Care Syndrome. <i>Journal of Nervous and Mental Disease</i> , 2021, 209, 242-243.	1.0	0
24	ADHD and Bipolar Disorder in Adulthood: Clinical and Treatment Implications. <i>Medicina (Lithuania)</i> , 2021, 57, 466.	2.0	15
25	â€Z-tripâ€™? A Comprehensive Overview and a Case-series of Zolpidem Misuse. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 367-387.	2.0	10
26	Peer Learning, Research, and Support in Times of the COVID-19 Pandemic: a Case Study of the Early Career Psychiatrists Model. <i>Academic Psychiatry</i> , 2021, 45, 613-618.	0.9	9
27	Challenges and Opportunities of Psychiatric Training During COVID-19: Early Career Psychiatristsâ€™ Perspective Across the World. <i>Academic Psychiatry</i> , 2021, 45, 656-657.	0.9	12
28	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 580.	2.0	16
29	COVID-19-induced psychosis: new challenges for early career psychiatrists. <i>I P Pavlov Russian Medical Biological Herald</i> , 2021, 29, 325-331.	0.5	1
30	A Systematic Review on TeleMental Health in Youth Mental Health: Focus on Anxiety, Depression and Obsessive-Compulsive Disorder. <i>Medicina (Lithuania)</i> , 2021, 57, 793.	2.0	31
31	Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: focus on second-generation long acting injectable antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1207-1224.	2.4	7
32	Peripheral BDNF levels in psychiatric patients with and without a history of suicide attempt: A systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110342.	4.8	20
33	The interactions between attention deficit hyperactivity syndrome and addictions. <i>I P Pavlov Russian Medical Biological Herald</i> , 2021, 29, 435-443.	0.5	0
34	The impact of a regional training program on peripartum depression in territorial psychiatric services. <i>European Psychiatry</i> , 2021, 64, S181-S182.	0.2	0
35	Training and education in digital psychiatry: A perspective from Asia-Pacific region. <i>Asia-Pacific Psychiatry</i> , 2021, 13, e12501.	2.2	14
36	P.0010 Psychiatry traineesâ€™ attitudes, knowledge and training in addiction psychiatry - a European survey. <i>European Neuropsychopharmacology</i> , 2021, 53, S8-S9.	0.7	0

#	ARTICLE	IF	CITATIONS
37	P.0813 Digital Psychiatry in the COVID-19 era: the first Italian cross-sectional survey. <i>European Neuropsychopharmacology</i> , 2021, 53, S594.	0.7	0
38	How to overcome barriers to publication in low- and middle-income countries: Recommendations from early career psychiatrists and researchers from around the world. <i>Asia-Pacific Psychiatry</i> , 2021, 13, e12495.	2.2	5
39	P.0646 The impact of the Covid-19 pandemic on peripartum affective psychopathology. <i>European Neuropsychopharmacology</i> , 2021, 53, S476.	0.7	0
40	The effect of paliperidone palmitate long-acting injectable (PP-LAI) on "non-core" symptoms of schizophrenia: a retrospective, collaborative, multicenter study in the "real world" everyday clinical practice. <i>Rivista Di Psichiatria</i> , 2021, 56, 143-148.	0.6	2
41	Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review. <i>Substance Use and Misuse</i> , 2020, 55, 304-313.	1.4	13
42	Alexithymia, resilience, somatic sensations and their relationships with suicide ideation in drug naïve patients with first-episode major depression: An exploratory study in the "real world" everyday clinical practice. <i>Microbial Biotechnology</i> , 2020, 14, 336-342.	1.7	30
43	Alexithymia, suicide ideation, affective temperaments and homocysteine levels in drug naïve patients with post-traumatic stress disorder: an exploratory study in the everyday "real world" clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2020, 24, 83-87.	2.4	36
44	Editorial: "No Words for Feelings, Yet!" Exploring Alexithymia, Disorder of Affect Regulation, and the "Mind-Body" Connection. <i>Frontiers in Psychiatry</i> , 2020, 11, 593462.	2.6	11
45	COVID-19 mental health care toolkit: an international collaborative effort by Early Career Psychiatrists section. <i>Annals of General Psychiatry</i> , 2020, 33, e100270.	3.1	23
46	Up-to-date expert opinion on the safety of recently developed antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 981-998.	2.4	34
47	Infectious disease outbreak related stigma and discrimination during the COVID-19 pandemic: Drivers, facilitators, manifestations, and outcomes across the world. <i>Brain, Behavior, and Immunity</i> , 2020, 89, 555-558.	4.1	112
48	Telepsychiatry During the COVID-19 Pandemic: Development of a Protocol for Telemental Health Care. <i>Frontiers in Psychiatry</i> , 2020, 11, 552450.	2.6	32
49	Unable to Describe My Feelings and Emotions Without an Addiction: The Interdependency Between Alexithymia and Addictions. <i>Frontiers in Psychiatry</i> , 2020, 11, 543346.	2.6	11
50	Emotional Dysregulation in Adolescents: Implications for the Development of Severe Psychiatric Disorders, Substance Abuse, and Suicidal Ideation and Behaviors. <i>Brain Sciences</i> , 2020, 10, 591.	2.3	38
51	The "collateral side" of mood stabilizers: safety and evidence-based strategies for managing side effects. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1461-1495.	2.4	7
52	Global Perspective and Ways to Combat Stigma Associated with COVID-19. <i>Indian Journal of Psychological Medicine</i> , 2020, 42, 569-574.	1.5	22
53	Digital Phenotyping in Bipolar Disorder: Which Integration with Clinical Endophenotypes and Biomarkers?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7684.	4.1	20
54	Can COVID-19 related mental health issues be measured?. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 32-34.	4.1	82

#	ARTICLE	IF	CITATIONS
55	Historical and clinical considerations on Ekblom's syndrome. <i>International Review of Psychiatry</i> , 2020, 32, 424-436.	2.8	11
56	The "dead man walking" disorder: an update on Cotard's syndrome. <i>International Review of Psychiatry</i> , 2020, 32, 500-509.	2.8	12
57	How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy. <i>Human Psychopharmacology</i> , 2020, 35, e2728.	1.5	11
58	Earthquakes, economic crisis and, now, COVID-19: the cry of yell of Central Italy.. <i>Psychiatry Research</i> , 2020, 291, 113181.	3.3	4
59	Telepsychiatry and healthcare access inequities during the COVID-19 pandemic. <i>Asian Journal of Psychiatry</i> , 2020, 53, 102234.	2.0	50
60	Mental Health Interventions during the COVID-19 Pandemic: A Conceptual Framework by Early Career Psychiatrists. <i>Asian Journal of Psychiatry</i> , 2020, 51, 102085.	2.0	125
61	Psychiatry Trainees' Attitudes, Knowledge, and Training in Addiction Psychiatry—A European Survey. <i>Frontiers in Psychiatry</i> , 2020, 11, 585607.	2.6	9
62	COVID-19 effect on mental health: patients and workforce. <i>Lancet Psychiatry</i> , 2020, 7, e29-e30.	7.4	110
63	Adjunctive vortioxetine for SSRI-resistant major depressive disorder: a "real-world" chart review study. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 317-321.	1.7	14
64	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 554-584.	2.1	25
65	"New/Designer Benzodiazepines": An Analysis of the Literature and Psychonauts' Trip Reports. <i>Current Neuropharmacology</i> , 2020, 18, 809-837.	2.9	51
66	Understanding the Complex of Suicide in Depression: from Research to Clinics. <i>Psychiatry Investigation</i> , 2020, 17, 207-221.	1.6	186
67	Personality Features and Defense Styles in Subjects Affected with Eating Disorders: Focus on Anorexia and Bulimia Nervosa. <i>Journal of Psychology and Psychotherapy Research</i> , 2020, 7, 98-106.	0.2	0
68	Characteristics of deaths associated with kratom use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1102-1123.	4.0	67
69	Use of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD): A Systematic Review. <i>Medicina (Lithuania)</i> , 2019, 55, 525.	2.0	80
70	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 1253-1264.	2.8	16
71	Benzodiazepines and Z-Drugs in Pregnancy. , 2019, , 203-213.		3
72	General Approach to Pharmacological Treatment: During the Perinatal Period. , 2019, , 55-66.		3

#	ARTICLE	IF	CITATIONS
73	Psychedelic fauna for psychonaut hunters. <i>European Neuropsychopharmacology</i> , 2019, 29, S472-S473.	0.7	0
74	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019, 6, 140-152.	3.4	7
75	The FDA "Black Box" Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?. <i>Frontiers in Psychiatry</i> , 2019, 10, 294.	2.6	50
76	The Bridge Between Classical and "Synthetic" Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. <i>Frontiers in Psychiatry</i> , 2019, 10, 851.	2.6	24
77	Norman Sartorius: psychiatry's living legend. <i>Lancet Psychiatry</i> , 2019, 6, 983-984.	7.4	3
78	When Clozapine Fails: Augmentation Strategies in the Management of Clozapine-Resistant Schizophrenia. , 2019, , 349-367.		3
79	Novel Pathways in the Treatment of Major Depression: Focus on the Glutamatergic System. <i>Current Pharmaceutical Design</i> , 2019, 25, 381-387.	1.9	33
80	The "hidden" and "forgotten" psychiatry: The Perinatal Psychiatry. <i>Rivista Sperimentale Di Freniatria</i> , 2019, , 35-58.	0.1	1
81	Alexithymia, Suicide Ideation and Homocysteine Levels in Drug Naïve Patients with Major Depression: A Study in the "Real World" Clinical Practice. <i>Clinical Psychopharmacology and Neuroscience</i> , 2019, 17, 318-322.	2.0	29
82	Alcohol Use Disorders. , 2019, , 315-323.		0
83	Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. <i>Therapeutic Advances in Drug Safety</i> , 2018, 9, 237-256.	2.4	130
84	Atypical Antipsychotics in Major Depressive Disorder. , 2018, , 257-268.		2
85	Creativity and psychiatric illness: A functional perspective beyond chaos. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 80, 91-100.	4.8	7
86	Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2888.	4.1	137
87	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2018, 9, 153.	2.6	10
88	CHAPTER 8. Novel Psychoactive Substances (NPS) and Recent Scenarios: Epidemiological, Anthropological and Clinical Pharmacological Issues. <i>Comprehensive Series in Photochemical and Photobiological Sciences</i> , 2018, , 207-256.	0.3	6
89	Protein-C Reactive as Biomarker Predictor of Schizophrenia Phases of Illness? A Systematic Review. <i>Current Neuropharmacology</i> , 2018, 16, 583-606.	2.9	72
90	Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 505-507.	2.0	2

#	ARTICLE	IF	CITATIONS
91	Clozapine-related Sudden Pericarditis in a Patient Taking Long Acting Aripiprazole and Valproate: A Case Report. <i>Clinical Psychopharmacology and Neuroscience</i> , 2018, 16, 505-507.	2.0	11
92	Spice Drugs, Synthetic Cannabinoids, and "Spiceophrenia"™. , 2018, , 159-168.		0
93	Is there a potential of misuse for <i>Magnolia officinalis</i> compounds/metabolites?. <i>Human Psychopharmacology</i> , 2017, 32, e2595.	1.5	13
94	Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice. <i>CNS Spectrums</i> , 2017, 22, 342-347.	1.2	43
95	The EFPT-PSUD survey. <i>European Psychiatry</i> , 2017, 41, S482-S483.	0.2	0
96	An insight into the deep web; why it matters for addiction psychiatry?. <i>Human Psychopharmacology</i> , 2017, 32, e2573.	1.5	48
97	From concept(ion) to life after death/the grave: The "natural" history and life cycle(s) of novel psychoactive substances (NPS). <i>Human Psychopharmacology</i> , 2017, 32, e2566.	1.5	30
98	Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?. <i>Current Neuropharmacology</i> , 2017, 15, 731-737.	2.9	21
99	Alexithymia and Suicide Risk in Psychiatric Disorders: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 148.	2.6	118
100	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017, 8, 240.	2.6	75
101	Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions. <i>International Journal of Molecular Sciences</i> , 2017, 18, 135.	4.1	57
102	The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review. <i>International Journal of Molecular Sciences</i> , 2017, 18, 349.	4.1	30
103	Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews. <i>BioMed Research International</i> , 2017, 2017, 1-17.	1.9	23
104	Cariprazine (RGH-188): a new pharmacological target option for the treatment of schizophrenia, bipolar disorders and depression?. <i>Minerva Psychiatry</i> , 2017, 58, .	0.3	1
105	Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. <i>Current Neuropharmacology</i> , 2017, 15, 750-761.	2.9	36
106	Current and Future Perspectives on the Major Depressive Disorder: Focus on the New Multimodal Antidepressant Vortioxetine. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 65-92.	1.4	25
107	Suicide Prevention in Schizophrenia: Do Long-Acting Injectable Antipsychotics (LAIs) have a Role?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 454-462.	1.4	27
108	Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics ("Spice") Intake?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 585-591.	1.4	11

#	ARTICLE	IF	CITATIONS
109	Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 598-609.	1.4	25
110	Lisdexamfetamine in the treatment of moderate-to-severe binge eating disorder in adults: systematic review and exploratory meta-analysis of publicly available placebo-controlled, randomized clinical trials. <i>Neuropsychiatric Disease and Treatment</i> , 2016, Volume 12, 1827-1836.	2.2	21
111	Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials. <i>Mediators of Inflammation</i> , 2016, 2016, 1-8.	3.0	30
112	Suicide during Perinatal Period: Epidemiology, Risk Factors, and Clinical Correlates. <i>Frontiers in Psychiatry</i> , 2016, 7, 138.	2.6	115
113	A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 35-44.	1.4	53
114	New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 483-495.	2.8	18
115	Aripiprazole for relapse prevention and craving in alcohol use disorder: current evidence and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 719-728.	4.1	35
116	NPS: Medical Consequences Associated with Their Intake. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 32, 351-380.	1.7	29
117	The consequences of drug misuse on post-marketing surveillance. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 867-871.	3.1	15
118	The novel antipsychotic cariprazine (RGH-188): State-of-the-art in the treatment of psychiatric disorders. <i>European Psychiatry</i> , 2016, 33, s228-s228.	0.2	1
119	Inflammatory markers and suicidal attempts in depressed patients: A review. <i>International Journal of Immunopathology and Pharmacology</i> , 2016, 29, 583-594.	2.1	27
120	An update of safety of clinically used atypical antipsychotics. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1329-1347.	2.4	112
121	Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 943-954.	3.1	47
122	The prevalence and predictors of bipolar and borderline personality disorders comorbidity: Systematic review and meta-analysis. <i>Journal of Affective Disorders</i> , 2016, 195, 105-118.	4.1	92
123	The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. <i>Current Pharmaceutical Design</i> , 2016, 22, 5144-5162.	1.9	25
124	Venlafaxine as the "baby ecstasy"? Literature overview and analysis of web-based misusers' experiences. <i>Human Psychopharmacology</i> , 2015, 30, 255-261.	1.5	14
125	Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. <i>Human Psychopharmacology</i> , 2015, 30, 302-318.	1.5	58
126	Novel psychoactive substances of interest for psychiatry. <i>World Psychiatry</i> , 2015, 14, 15-26.	10.4	257

#	ARTICLE	IF	CITATIONS
127	Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Human Psychopharmacology</i> , 2015, 30, 4-20.	1.5	83
128	Mind Navigators of Chemicals' Experimenters? A Web-Based Description of E-Psychonauts. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2015, 18, 296-300.	3.9	66
129	Targeting the Noradrenergic System in Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis of Prazosin Trials. <i>Current Drug Targets</i> , 2015, 16, 1094-1106.	2.1	89
130	“Noids” in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics. <i>Advances in Dual Diagnosis</i> , 2014, 7, 137-148.	0.5	21
131	Safety of escitalopram in pregnancy: a case series. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1333.	2.2	5
132	The safety of escitalopram during pregnancy and breastfeeding: a comprehensive review. <i>Human Psychopharmacology</i> , 2012, 27, 534-539.	1.5	15